logo
logo

Tilt Biotherapeutics Announces Over $10 Million Financing To Advance Oncology Immunotherapy Assets

Tilt Biotherapeutics Announces Over $10 Million Financing To Advance Oncology Immunotherapy Assets

06/14/22, 11:00 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/FI.svghelsinki
Money raised
$10 million
TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces it has completed the first close of its financing round raising $10.7 million (€10 million). The round was led by Lifeline Ventures and was joined by Tesi (Finnish Industry Investment Ltd). The funding will be used to advance Phase I/II programs in Europe and the US, using TILT-123 plus immune checkpoint inhibitors against a range of cancers including ovarian, head & neck, and lung.

Company Info

Company
Tilt Biotherapeutics
Location
helsinki, etelä-suomi, finland
Additional Info
TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary oncolytic adenoviruses armed with molecules including cytokines that can stimulate, or suppress, T cells. The company’s patented TILT® technology, which can be delivered locally and systemically, modifies the tumor microenvironment, and eliminates its ability to suppress immune responses to cancer, thereby enhancing T-cell therapies such as checkpoint inhibitors and CAR T therapies.